2.125% convertible senior notes due 2028
Note · Innoviva, Inc.
Reference: 2.125% convertible senior notes due 2028
- Original principal
- USD 225,000,000
- Outstanding
- —
- Commitment
- —
- Availability
- —
- Maturity
- —
Last reported interest terms: 2.125% Reported 2022-03-21 Later filings may not restate these terms; this does not confirm they still apply.
Covenant terms for this agreement are not yet verified.
Documents and filing history
- PeriodicDisclosure · 8-K · 2022-03-21 — FORM 8-K
- Issuance · 8-K · 2022-03-21 — FORM 8-K
-
AdditionalIssuance
· 2022-03-18
Original principal USD 36,000,000 Exact source document
Parent 8-K filing · 2022-03-21
On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
Issuer evidence: On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
Supporting evidence: On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
-
Issuance
· 2022-03-07
Original principal USD 225,000,000 Exact source document
Parent 8-K filing · 2022-03-21
On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
Issuer evidence: On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
Supporting evidence: On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.